Darovasertib (LXS196): Selectivity & Specificity
Darovasertib (LXS196) is a potent inhibitor of PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ, MARCKS (inhibited), MAPK1 (inhibited), MAPK3 (inhibited), SLC1A2 (decreased expression by 33% (at 6mg/kg)). Darovasertib (LXS196) exhibits the greatest inhibitory potency toward PRKCA.